Dystrophin Market to Reach USD USD 30.22 Billion Billion by 2028
The Dystrophin Market is expected to reach USD USD 30.22 Billion billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 45.9% in between 2022 to 2028. A deficiency or absence of Dystrophin is accountable for two disorders that cause progressive muscle destruction. The absence of this drug impairs the honour of the sarcolemma membrane, assimilating the membrane exposed to mechanical damage.
- The Exon Skipping segment is projected to grow at a Significant Compound Annual Growth Rate (CAGR). Due to expected adoption worldwide after regulatory approval in Europe as well as in other parts of the globe. However, a lack of awareness with respect to therapeutics in emerging nations is likely to hinder its growth in the coming years.
- North America is likely to expand at a substantial rate in the forecast period on account of the new product launches in the U.S. Determinants such as the high prevalence of muscular dystrophy in North America, accelerated approval of the drug by FDA in the region, appropriate funding circumstances for research & development in the area of DMD, huge healthcare expenditure capacity among the population in North America, availability of medical compensation in the region are the key factors facilitating the growth of Dystrophin Market in the region.
Some of key players in Dystrophin Market is - PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis, Pharmaceuticals among others..
The market is defined by the entry of a big number of market players that include developing companies, as well as pharma giants. The key factor, for the focus of these players, is the untapped demand for muscular dystrophy diseases treatment for a long time. There are more than 35 companies committed in clinical trials for the novel therapeutics launch for the treatment of DMD. Owing to strict regulation for drug approval across the globe, very few drug applicants received approval from regulatory bodies in medicine such as the U.S. FDA and European Commission.
Asia Pacific market is likely to reflect substantial growth in the coming years due to expecting drug launches in the region. A suitable scenario for funds for research and development and the presence of numerous emerging market players in the region is anticipated to promote the growth of the market over the forecast period.
The Dystrophin is segmented as follows:
Browse market data Tables and Figures
Pages and in-depth TOC on "Dystrophin Market by Product (Exondys51, Translarna, Emflaza, Others), by Approach (Exon Skipping, Anti-Inflammatory Therapy, Stop Codon Read-Through, Others Approaches), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)"
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
Vantage Market Research is a reputed company committed to providing high quality data and market research services. The company provides quantified B2B high quality research on more than 20,000 emerging markets. The company offers detailed reports on multiple industries including chemical materials and energy, food and beverages, healthcare, technology, etc. The company comprises over 125 analysts and consultants, adding more than 1,100 market research reports to its vast database every year. The company’s clientele base spans across 70% of the Global Fortune 500 companies.